VEGFR2/CD309 anticorps

N° du produit ABIN6265973

Détail du produit anti-VEGFR2/CD309 anticorps

Antigène: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp VEGFR2/CD309 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (IHC), ELISA, Immunofluorescence (IF), Immunocytochemistry (ICC)

Specificité: VEGFR2 Antibody detects endogenous levels of total VEGFR2

Réactivité croisée: Humain, Souris, Rat (Rattus)

Purification: The antiserum was purified by peptide affinity chromatography using SulfoLink^TM Coupling Resin (Thermo Fisher Scientific).

Immunogène: A synthesized peptide derived from human VEGFR2

Isotype: IgG

Information d'application

Indications d'application: WB 1:500-1:2000 IHC 1:50-1:200 IF 1:200

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS,  pH 7.4,50 % glycerol.

Références pour anticorps anti-VEGFR2/CD309 (ABIN6265973)

Zhang, Chen, Wang, Yang, Li, Wang, Liu, Ye: "Treatment of diabetes mellitus-induced erectile dysfunction using endothelial progenitor cells genetically modified with human telomerase reverse transcriptase." dans: Oncotarget, Vol. 7, Issue 26, pp. 39302-39315, (2018) (PubMed).

Gu: "IL13Rα2 siRNA inhibited cell proliferation, induced cell apoptosis, and suppressed cell invasion in papillary thyroid carcinoma cells." dans: OncoTargets and therapy, Vol. 11, pp. 1345-1352, (2018) (PubMed).

Wang, Shen, Liu, Ning, Wu, Huang: "TRIM24 siRNA induced cell apoptosis and reduced cell viability in human nasopharyngeal carcinoma cells." dans: Molecular medicine reports, Vol. 18, Issue 1, pp. 369-376, (2018) (PubMed).

Meng, Chen, Lei, Han, Zhong, Wang, Liu, Gao, Zhang, Tan, Liu, Zhou, Sun, Yang: "Hsp90β promotes aggressive vasculogenic mimicry via epithelial-mesenchymal transition in hepatocellular carcinoma." dans: Oncogene, (2018) (PubMed).

Wu, Zheng, Bai, Xia, Zhang, Guo: "HMGB1/RAGE axis mediates the apoptosis, invasion, autophagy, and angiogenesis of the renal cell carcinoma." dans: OncoTargets and therapy, Vol. 11, pp. 4501-4510, (2018) (PubMed).

Détails sur VEGFR2/CD309

Antigène: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Autre désignation: VEGFR2 (VEGFR2 Produits)

Sujet:

Description: Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA- and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC.

Gene: KDR

Poids moléculaire: 180kDa

ID gène: 3791

UniProt: P35968

Pathways: Signalisation RTK, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling